Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Refractory anemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    143 result(s) found for: Refractory anemia. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2005-004737-17 Sponsor Protocol Number: DARB-MDS Start Date*: Information not available in EudraCT
    Sponsor Name:AZIENDA OSPEDALIERA BIANCHI-MELACRINO-MORELLI
    Full Title: Evaluation of the Efficacy of Darbepoetin Alfa for the Treatment of Anemia in Patients with Myelodysplastic Syndrome
    Medical condition: Anemia in patients with myelodysplastic syndrome.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10038269 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001257-22 Sponsor Protocol Number: 20210112 Start Date*: 2023-03-29
    Sponsor Name:Amgen, Inc.
    Full Title: Two Arm Bridging Study to Evaluate the Efficacy of Romiplostim in the Treatment of Non Asian Adult Severe Aplastic Anemia (SAA) Subjects who are Either Previously Untreated With Immunosuppressive T...
    Medical condition: Aplastic anemia (AA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10002967 Aplastic anaemia PT
    20.1 10005329 - Blood and lymphatic system disorders 10002968 Aplastic anaemia, unspecified LLT
    23.0 10005329 - Blood and lymphatic system disorders 10083893 Acquired aplastic anaemia LLT
    20.0 10005329 - Blood and lymphatic system disorders 10032510 Other specified aplastic anaemias LLT
    20.0 10005329 - Blood and lymphatic system disorders 10002969 Aplastic anemia LLT
    20.0 10005329 - Blood and lymphatic system disorders 10002037 Anaemia aplastic LLT
    20.0 10005329 - Blood and lymphatic system disorders 10002274 Anemia aplastic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011613-24 Sponsor Protocol Number: HOVON102AML/SAKK30/09 Start Date*: 2010-01-25
    Sponsor Name:HOVON Foundation
    Full Title: Randomized study with a run-in feasibility phase to assess the added value of Clofarabine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously ...
    Medical condition: - a cytopathologically confirmed diagnosis of AML according WHO classification (excluding acute promyelocytic leukaemia) or - a diagnosis of refractory anemia with excess of blasts (RAEB) and ...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054592 Refractory anemia with an excess of blasts LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038270 Refractory anaemia with an excess of blasts PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066353 Treatment related acute myeloid leukemia LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000348-22 Sponsor Protocol Number: KER047-IR-201 Start Date*: 2021-08-10
    Sponsor Name:Keros Therapeutics, Inc.
    Full Title: A Phase 2, Open-label, Dose Escalation and Dose Expansion Study of KER-047 for the Treatment of IRIDA
    Medical condition: Iron-Refractory Iron-Deficiency Anemia (IRIDA)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005322-22 Sponsor Protocol Number: RV-MDS-PI-0550-REV/AZA Start Date*: 2012-06-11
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: A Phase II Study exploring the feasibility of Azacitidine and Lenalidomide use (combination vs sequential treatment) for Higher-Risk Myelodysplastic Syndromes (MDS) (IPSS Risk: High or INT-2)
    Medical condition: Higher-Risk Myelodysplastic Syndromes (MDS) (IPSS Risk: High or INT-2)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002311 Anemia refractory LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028532 Myelodysplasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005370-62 Sponsor Protocol Number: ANAKIN-RA-DIABETES Start Date*: 2013-02-18
    Sponsor Name:OSPEDALE CIVILE SAN SALVATORE, ASL 04, L'AQUILA
    Full Title: “No-profit” clinical study for the improvement of clinical practice, to evaluate the efficacy of anakinra in reducing the glycated haemoglobin in patients affected by rheumatoid arthritis and diabe...
    Medical condition: rheumatoid arthritis and type 2 diabetes mellitus as comorbidity.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004859 10037740 RA LLT
    14.1 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005264-14 Sponsor Protocol Number: P130103 Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: NA
    Medical condition: Fanconi Anemia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004850 10055206 Fanconi's anemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-006329-42 Sponsor Protocol Number: CAD0111 Start Date*: 2012-10-11
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
    Full Title: Short course of Bortezomib in anemic patients with refractory cold agglutinin disease
    Medical condition: Anaemia with refractory cold agglutinin disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10009868 Cold type haemolytic anaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002502-31 Sponsor Protocol Number: RP-L102-0118 Start Date*: 2018-10-31
    Sponsor Name:Rocket Pharmaceuticals, Inc.
    Full Title: A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene (Orphan Drug) in Patients with Fanconi Anemi...
    Medical condition: Fanconi anemia (subtype A)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10055206 Fanconi's anemia LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-003166-91 Sponsor Protocol Number: CETB115E2201 Start Date*: 2019-05-22
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase II, open-label, non-controlled, intra-patient dose escalation study to characterize the pharmacokinetics after oral administration of eltrombopag in pediatric patients with refractory, rela...
    Medical condition: Refractory, relapsed or treatment naïve severe aplastic anemia (SAA) or recurrent aplastic anemia (AA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10002967 Aplastic anaemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PT (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-001223-31 Sponsor Protocol Number: KAISII Start Date*: 2016-10-11
    Sponsor Name:King's College Hospital NHS Foundation Trust
    Full Title: Incidence of Invasive Fungal Disease in Patients receiving Immunosuppressive Therapy, Intensive Chemotherapy or Reduced Intensity Haematopoietic Stem Cell Transplantation on Posaconazole Prophylaxis
    Medical condition: Aplastic Anaemia, Myelodysplastic syndromes, Acute Myeloid Leukaemia undergoing immunosuppression therapy, high dose chemotherapy or reduced intensity stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038271 Refractory anaemia with excess blasts in transformation LLT
    19.0 10042613 - Surgical and medical procedures 10059041 Allogeneic peripheral haematopoietic stem cell transplant LLT
    19.0 10042613 - Surgical and medical procedures 10067862 Allogeneic stem cell transplantation LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038270 Refractory anaemia with an excess of blasts PT
    19.0 10005329 - Blood and lymphatic system disorders 10010776 Constitutional aplastic anaemia LLT
    19.0 10005329 - Blood and lymphatic system disorders 10068063 Aplastic anaemia relapse LLT
    19.0 10005329 - Blood and lymphatic system disorders 10036699 Primary idiopathic aplastic anaemia LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    19.0 10042613 - Surgical and medical procedures 10001756 Allogenic bone marrow transplantation therapy PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000884 Acute myeloid leukaemia NOS LLT
    19.0 10005329 - Blood and lymphatic system disorders 10032510 Other specified aplastic anaemias LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066355 Treatment related acute myeloid leukaemia LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060355 Acute myeloid leukaemia in remission LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028532 Myelodysplasia LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066764 Acute myeloid leukaemia progression LLT
    19.0 10005329 - Blood and lymphatic system disorders 10002967 Aplastic anaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003675-18 Sponsor Protocol Number: ANX005-wAIHA-02 Start Date*: 2021-01-11
    Sponsor Name:Annexon, Inc.
    Full Title: A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Proof-of-Concept of Intravenous ANX005 in Subjects with Warm Autoimmune Hemolyti...
    Medical condition: Warm Autoimmune Hemolytic Anemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10003825 Autoimmune hemolytic anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) FR (Completed) CZ (Completed) BG (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006197-88 Sponsor Protocol Number: FANCOSTEM-1 Start Date*: 2012-03-22
    Sponsor Name:Cristina Díaz de Heredia Rubio
    Full Title: Clinical Phase II Trial to evaluate efficacy and safety of CD34+ cells mobilization and collection after treatment with plerixafor and filgrastim in patients with Fanconi anemia for subsequent tra...
    Medical condition: Fanconi anemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10055206 Fanconi's anemia LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-000404-92 Sponsor Protocol Number: HOVON 92 AML Start Date*: 2008-09-12
    Sponsor Name:HOVON Foundation
    Full Title: Randomized study to assess the added value of Laromustine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia...
    Medical condition: AML according to WHO classification (excluding acute promyelocytic leukaemia) or refractory anemia with excess of blasts (RAEB) and IPSS score ≥1.5 or therapy-related AML/RAEB or biphenotypic le...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000886 Acute myeloid leukemia LLT
    9.1 10054593 Refractory anemia with excess blasts in transformation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-006100-12 Sponsor Protocol Number: FANCOLEN-1 Start Date*: 2013-04-12
    Sponsor Name:FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO NIÑO JESUS
    Full Title: Clinical Trial Phase I / II to evaluate the safety and efficacy of the infusion of autologous CD34+ cells transduced with a lentiviral vector carrying the FANCA gene (orphan drug) for patients with...
    Medical condition: Fanconi anemia (Subtype A)
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004850 10055206 Fanconi's anemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016966-97 Sponsor Protocol Number: CAD01 Start Date*: 2010-06-08
    Sponsor Name:Universitätsklinikum Essen
    Full Title: Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-Randomized, Multi-Center Study Demonstrating the Efficacy of Terminal Complement Inhibition in Patients with Cold Agglutinin Disease ...
    Medical condition: Cold agglutinin disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009868 Cold type haemolytic anaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002652-33 Sponsor Protocol Number: T-Haplo-for-SCD Start Date*: Information not available in EudraCT
    Sponsor Name:University Hospital of Regensburg
    Full Title: A phase 2 trial to assess haploidentical Alpha/ß T-depleted stem cell transplantation in patients with sickle cell disease with no available sibling donor
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014455-68 Sponsor Protocol Number: HOVON103AMLTosedostat Start Date*: 2010-08-16
    Sponsor Name:HOVON Foundation
    Full Title: A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral tosedostat to standard induction therapy in AML and RAEB ≥ 66 years and ...
    Medical condition: patients ≥ 66 years.with a confirmed diagnosis of o AML (not APL) (see appendix A) or o refractory anemia with excess of blasts (RAEB) with an IPSS score ≥ 1.5 OR Patients of any age ≥ 1...
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10037803 RAEB LLT
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Completed) NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013094-17 Sponsor Protocol Number: HOVON103AMLLEN Start Date*: 2010-04-13
    Sponsor Name:HOVON Foundation
    Full Title: A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral lenalidomide to standard induction therapy in AML and RAEB ≥ 66 years an...
    Medical condition: patients ≥ 66 years.with a confirmed diagnosis of o AML (not APL) (see appendix A) or o refractory anemia with excess of blasts (RAEB) with an IPSS score ≥ 1.5 OR Patients of any age ≥ 1...
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10037803 RAEB LLT
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Completed) NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003227-15 Sponsor Protocol Number: KER050-MF-301 Start Date*: 2022-02-08
    Sponsor Name:Keros Therapeutics, Inc.
    Full Title: A Phase 2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KER-050 as Monotherapy or in Combination with Ruxolitinib in Participants with Myelofibrosis
    Medical condition: Myelfibrosis (MF) MF- associated cytopenias
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    20.0 100000004851 10002272 Anemia LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074690 Post essential thrombocythemia myelofibrosis LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074691 Post polycythaemia vera myelofibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 04 02:20:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA